



 **aaps**
National 
Biotechnology
CONFERENCE

APR
23-26 | **2023**

PHILADELPHIA
MARRIOTT DOWNTOWN
PHILADELPHIA, PA

CALL FOR POSTER ABSTRACTS

AAPS seeks poster abstract submissions that present data-driven, novel research in the pharmaceutical sciences.

MEETING TRACKS:



**ADVANCES IN
THERAPEUTIC
DEVELOPMENT
ACROSS
MODALITIES**



**TURBOCHARGING
INNOVATION IN
CMC—DRIVING
BACK TO RATIONAL
DRUG DESIGN**

TABLE OF CONTENTS

TRACKS	3
Advances in Therapeutic Development Across Modalities	3
Turbocharging Innovation in CMC—Driving Back to Rational Drug Design	3
IMPORTANT DATES (all dates subject to change)	4
Poster Abstract Submissions	4
ABSTRACT AND POSTER POLICY	5
Permissions/Clearances	5
Registration Requirement for Participation and Publication	5
Posters Must Include the Accepted Abstract	5
ABSTRACT FORMAT	6
Acceptance Criteria	6
Rejections	6
Encore Presentations	7
Abstract Revisions	7
Notification of Receipt and Verification of Submission	7
SCREENING PROCESS	8
Notification of Acceptance/Rejection	8
Appeals	8
Registration Requirement	9
Change in Presenting Author	9
Cancellation Policy and Substitution	9
Abstract/Poster Withdrawal	9
POSTER FORMAT REQUIREMENTS	10
FREQUENTLY ASKED QUESTIONS	10
POSTER ABSTRACT TRACKS/ THEMES/KEYWORDS	11

TRACK-BASED PROGRAMMING

EACH ABSTRACT PROPOSAL MUST RELATE TO ONE OF THE FOLLOWING TWO TRACKS:

TRACK 1



ADVANCES IN THERAPEUTIC DEVELOPMENT ACROSS MODALITIES

Recent advances in therapeutic development across modalities, including gene therapy, cell therapy, and innovative therapies based on traditional modalities.

THEME 1:

Recent Advances in Gene Therapy

As the field of gene therapy expands in scope beyond orphan disease indications and learnings from ongoing clinical trials become available, the bioanalytical strategy to support this novel modality is developing. Discuss recent advances in this field, including biodistribution, pharmacodynamics, cellular immunogenicity, as well as how these fit into evolving regulatory guidance.

THEME 2:

The Evolution of Cellular Therapy

As cellular modalities expand across formats and indications, the technologies and practices for monitoring exposure, immunophenotyping, and clinical endpoints are rapidly advancing. Discuss these evolving strategies as well as considerations around allogeneic versus autologous therapies.

THEME 3:

Innovation Based on Traditional Approaches

Protein-small molecule hybrid (e.g., ADC), bi- and tri-specifics, oligonucleotides, and vaccine-based therapeutics are experiencing an exciting reemergence in innovation with new clinical findings. Discuss recent advances in biotransformation, PK/PD, and immunogenicity analyses to better assess safety and efficacy.

TRACK 2



TURBOCHARGING INNOVATION IN CMC—DRIVING BACK TO RATIONAL DRUG DESIGN

Beyond the innovation in drug discovery, pharmaceutical and biotechnology communities are embracing emerging opportunities and advancements in Chemistry, Manufacturing, and Controls (CMC) in all stages of the drug development life cycle. This track focuses on the emerging landscape of non-traditional platforms for drug delivery and novel modalities, such as cell and gene therapies. Discuss frontiers of drug and formulation design in biologics development, modern experimental, computational, intelligent analytics, regulatory perspective, and bioengineering.

THEME 1:

Innovation Based on Non-Traditional Platforms

Innovative technologies have been harnessed to integrate cutting-edge resources with scientific expertise in shaping the next wave of medical interventions. Discuss breakthroughs with drug design and analytical tools for novel modalities, innovations in vaccine approaches, enhancing scope and coverage of modalities using AI and machine learning, as well as regulatory guidance and perspective on future innovations in biotechnology.

THEME 2:

Next Generation Gene Therapies

Gene therapy advancements have revolutionized the treatment paradigm of a handful of rare disorders, from managing to curing the disease. The next wave of novel gene editing modalities will impact other therapeutic areas such as cancer, immune, and infectious diseases. Discuss coping with these advances in terms of improving patient stratification strategy, drug safety, and efficacy.

THEME 3:

Explosion of Cell Therapy Beyond CAR-T

The next wave of cell therapies goes beyond the traditional Chimeric Antigen Receptor (CAR) T-cell immunotherapy (CAR-T). Newcomers include universal allogeneic CAR, tumor-infiltrating lymphocytes (TILs) and adoptive cell immunotherapy such as CAR NK-cells. Discuss key advancements and challenges facing the adoption of these novel cell therapies, especially those related to drug design, safety, and supply chain.

IMPORTANT ABSTRACT DATES

POSTER ABSTRACT SUBMISSIONS

DEC

DECEMBER 1, 2022
Submission site opens

JAN

**JANUARY 25, 2023
AT 5 PM ET**
**DEADLINE: Poster Abstract
Submission Site Closes**

FEB

FEBRUARY 16, 2023
Abstract Accept/Reject
notifications sent

MAR

MARCH 3, 2023
**DEADLINE: Poster Presenting
Author Registration**

MARCH 9, 2023
Poster schedule notifications
sent to authors

MARCH 13, 2023
Authors begin uploading
completed posters

APR

APRIL 3, 2023
Deadline for uploading posters

APRIL 23-26, 2023
NBC takes place

ALL DATES SUBJECT TO CHANGE

ABSTRACT AND POSTER POLICY

By submitting an abstract for presentation at the AAPS National Biotechnology Conference, you agree to abide by the conditions and policies provided below, as well as the decisions of the Abstract Screening Committee and AAPS staff.

Direct questions about this (NBC) policy to abstracts@aaps.org.

PERMISSIONS/CLEARANCES

AAPS recommends the designated presenting author submit the abstract. The designated presenting author is responsible for obtaining the necessary permissions and clearances for all research, information, and graphics used in both the abstract and the poster, and will receive all abstract/poster-related communications. AAPS assumes no liability or responsibility for the publication of any material that is submitted.

Use of the AAPS logo in any abstract submission or poster presentation is STRICTLY PROHIBITED.

REGISTRATION REQUIREMENT FOR PARTICIPATION AND PUBLICATION

The presenting author is required to participate in the meeting to have the poster included in the collection. If the presenting author is unable to participate during the meeting, a coauthor is required to assume the responsibilities of the presenting author and represent the poster. If no authors are able to participate in the meeting, a presenter may be appointed who is not an author of the abstract.

The presenter or presenting author is required to register either as a full-conference, one-day, exhibitor, or exhibit-hall-only attendee for the meeting by the Presenting Author Registration Deadline, or AAPS will withdraw the abstract/poster. Withdrawn abstracts/posters will not be published online or included in the poster collection.

Exhibitors who are presenters or presenting authors must complete their registrations by the Presenting Author Registration Deadline, even if they are using an exhibitor registration provided by their employer.

POSTERS MUST INCLUDE THE ACCEPTED ABSTRACT

Posters that are uploaded for presentation must include the accepted abstract, including all methods used and data resulting from the research. **The title of the poster must match, verbatim, the title of the accepted abstract.**

Omitting data from a poster presentation that was included in the submitted abstract is unethical. Authors and organizations violating these requirements will be subject to penalties including withdrawal of their paper and their being barred from submitting to any future AAPS meeting.

ABSTRACTS MUST BE SUBMITTED TO THE SUBMISSION WEBSITE BY 5:00 PM ET ON THE INDICATED DEADLINE DATE.

Abstracts submitted after this deadline or by different means will be rejected without review.

DATA SUPPORTING THE CONCLUSION OF THE ABSTRACT MUST BE DEVELOPED PRIOR TO SUBMISSION.

Abstracts stating that data will be developed between the time of submission and the time of the meeting will be rejected without review.



USE THE GOOGLE CHROME BROWSER TO SUBMIT YOUR ABSTRACT.

The submission site is not compatible with Microsoft Edge/Internet Explorer as well as some other browsers.

The submission system can be accessed at the [Submission Site](#).

To ensure receipt of all abstract-related correspondence, add the following addresses to your contact list:

support@conferenceabstracts.com
scorecard@cadmiumcd.com
abstracts@aaps.org
homricht@aaps.org
appeals@aaps.org
posters@aaps.org

ABSTRACT FORMAT

ACCEPTANCE CRITERIA

Acceptance of the abstract for poster presentation will be based on the concise, accurate presentation of new data. It is imperative that data is presented in the Results section so that AAPS scientific screeners can judge the scientific value of your abstract. Include all research information, data, charts, and graphs in your submission so that it can be screened in its entirety. Abstracts will be reviewed and scored based on the following:

- Is the CONCLUSION of the research data driven?
- How EXCITING/NOVEL will viewers find this research?
- How well does the RESEARCH incrementally advance its field?
- How well does the author's selected strategy for evaluating the HYPOTHESIS suit the project?

REJECTIONS

AAPS reviews each abstract to ensure it is qualified for consideration. Abstracts that do not meet the requirements outlined above are rejected. Causes for rejection include:

- Lack of data
- Acknowledgements were included in the abstract, preventing a blind review
- Affiliation or company name(s) were included in the abstract, preventing a blind review (product names are permitted)
- Commerciality
- Inconsistent or ambiguous data
- Reviews of literature
- Lack of novelty or innovation
- Stating that data or information will be included in the poster presentation
- Previously published research
- Including previously published information in your research without referencing the information in the abstract submission
- Failure to follow format guidelines (Purpose, Methods, Results, Conclusion, References, Acknowledgements)
- Failure to upload tables or charts (if used) as images as directed. Tables and/or charts are not to be included in the text box for the Purpose, Methods, Results, or Conclusion. Tables and/or charts must be uploaded as images—refer to the Abstract Format section above.
- Failure to submit one strong abstract instead of several abstracts presenting the same work. The submission of multiple abstracts covering the same or similar work is discouraged and may be rejected by the committee.

ABSTRACTS MUST CONTAIN THE FOLLOWING ELEMENTS

DATA, including all research information either in paragraph format or in charts and graphs. AAPS rejects any abstract that is not based on data.

TITLE in headline style: 200-character limit with no period at the end

AUTHORS: Limit of 13 authors

PURPOSE: paragraph format

METHODS: paragraph format

RESULTS: paragraph format

CONCLUSIONS: paragraph format

REFERENCES: Reference any previously published material used in your research.

IMAGES in jpg format. **Do not include images in the Purpose, Methods, Results, or Conclusion sections.**

TABLES AND/OR CHARTS: Convert tables or charts to an image and upload in the Images section (3 images are allowed). **Do not include tables or charts in the Purpose, Methods, Results, or Conclusion sections.**

ACKNOWLEDGEMENTS, DISCLAIMERS, FUNDING, AND OTHER DISCLOSURE OR CONFLICT OF INTEREST STATEMENTS: This area should include any disclaimers, acknowledgements, funding, or other information that would prevent a blind review. This information will not be available to reviewers during the review process.

ABSTRACT LENGTH AND IMAGES

Abstracts may contain **a maximum of 800 words.**

1 to 3 images in jpg format may be included.

Data tables must be uploaded as one of three possible images and not included in the abstract text boxes.

ENCORE PRESENTATIONS

AAPS accepts encore presentations, which are unpublished abstracts and posters that have been presented elsewhere. No abstract or resulting poster may be displayed at the National Biotechnology Conference or any other AAPS event without the review and approval of the Abstract Screening Committee, regardless of prior presentation elsewhere.

ABSTRACT REVISIONS

- Revisions can be made at any time **before the poster abstract submission deadline** listed under the important dates.
- If you revise your abstract submission, you must be sure to save your changes and click Submit. Failure to complete all the steps will result in an incomplete submission, and your abstract will not be sent to the Abstract Screening Committee. Revisions cannot be made after the poster abstract submission deadline.
- Author names and affiliation or company names will be published as submitted. Be sure you have the correct and current author information. No changes may be made after the submission deadline, including adding or removing authors.
- Proofread, spell-check, and make sure all authors are listed on your abstract before submitting, as the abstracts will be presented in conference materials exactly as they appear at the time of submission.

NOTIFICATION OF RECEIPT AND VERIFICATION OF SUBMISSION

- You will receive an immediate email confirmation of completion when you have successfully submitted the abstract. This notification only confirms receipt of your submission and is not a notification of acceptance.
- If you do not receive an immediate email confirmation, your submission is not complete. You must return to the submission site to complete the submission process.
- If you return to the submission site to review or make changes to your abstract for any reason, you must complete all submission steps again in order to be sure your abstract is successfully submitted.

TOP 4 REASONS ABSTRACTS ARE REJECTED

Each year, AAPS rejects a few dozen abstracts – many “without review,” which means the abstracts were not qualified for consideration and were never shown to a panel of scientific screeners.

HERE ARE THE TOP 4 REASONS THIS HAPPENS:

1. The abstract did not contain any data.

AAPS will not accept an abstract that is not based on data that has already been developed.

2. The abstract is too commercial.

AAPS welcomes research conducted by any scientist, but does not permit sales pitches.

3. The abstract does not follow the formatting and guidelines outlined in this document.

4. The abstract contained author, company name, or affiliation, preventing a blind review process.

SCREENING PROCESS

QUALIFIED ABSTRACTS are reviewed by a blind panel of at least **3** scientists who score each abstract based on these questions:

QUESTION #1

Is the **CONCLUSION** of the research data driven?

QUESTION #2

How **EXCITING / NOVEL** will viewers find this research?

QUESTION #3

How well does the **RESEARCH** incrementally advance its field?

QUESTION #4

How well does the author's selected strategy for evaluating the **HYPOTHESIS** suit the project?

Abstracts are screened during a blind review process. No author or affiliation names may be included in the abstract Title, Purpose, Methods, Results, or Conclusion sections. Including this information in these areas will result in an automatic rejection of the abstract because a blind review would not be possible.

Authors of accepted abstracts and posters will abide by the decisions and instructions of AAPS. In the event that authors fail to follow AAPS' policies and instructions, their abstract(s) and/or poster(s) will be removed from AAPS' displays. Authors may also have their acceptances rescinded and, in extreme cases, may see themselves and the organizations they represent barred from future meetings.

NOTIFICATION OF ACCEPTANCE/REJECTION

Notification of accept/reject and other pre-submission deadline correspondence will be sent to the submitting author. Once a poster abstract is accepted, additional communications will be sent to the designated presenting author.

APPEALS

Appeals based on proposed additions or changes to an abstract or poster that has already been submitted will be rejected without consideration by AAPS as these changes constitute a new abstract or poster.

To appeal the rejection or withdrawal of an abstract or poster, the submitting author must email the following to appeals@aaps.org within 5 business days of AAPS issuing the rejection:

1. Email Subject Line: Appeal
[Abstract Submission ID Number]
2. Abstract title
3. Contact information for the submitter
4. Statement explaining on what grounds the author feels AAPS should reverse its decision

Appeals submitted by someone other than the submitter of the abstract, or by any means other than stated above, do not constitute an appeal and will be rejected without review.

Upon receiving a request for an appeal, the AAPS Screening Committee Chair will seat a Review Committee of three members. The Review Committee will:

1. Consider the policies and requirements for abstracts and posters as described in AAPS' materials
2. Review the abstract as submitted
3. Review the reasoning behind the rejection
4. Review the argument provided by the submitting author

The Review Committee will not consider any proposed changes to the abstract as submitted.

The final decision will be communicated to the author by email.

REGISTRATION REQUIREMENT

If selected for presentation, authors presenting posters must:

- Register as a full-conference, one-day, exhibitor, or exhibit-hall-only attendee for the 2023 AAPS National Biotechnology Conference by midnight ET on the **Presenting Author Registration Deadline** listed under important dates.
- The posters of authors who fail to register by the deadline will be withdrawn from AAPS' collection of posters.
- Coauthors may present in place of the presenting author if notification is made to AAPS at abstracts@aaps.org. The presenting coauthor must complete and pay for their registration before the change in presenting author can be made.
- A presenter who is not an author or coauthor of the abstract may present the poster if no authors are able to participate. Changes in the presenter or presenting author must be sent to AAPS at abstracts@aaps.org.
- Authors working in an exhibitor's booth may register as an exhibitor, but their registration must be completed by midnight ET on the **Presenting Author Registration Deadline** indicated under important dates.

CHANGE IN PRESENTING AUTHOR

All requests for a change in presenter or presenting author after the final submission deadline must be sent by the submitting author to AAPS at abstracts@aaps.org and include the Submission ID Number as well as the name and email address of the new presenter or presenting author. No authors may be added after the submission deadline.

POSTER SCHEDULE

AAPS will notify presenting authors of the scheduled day, time, and assigned poster number by email.

- If you do not receive notification, contact AAPS at abstracts@aaps.org for an update on the scheduling of your abstract.
- Notifications will be sent only to the designated presenting author.
- All posters will be included in the collection and available in the online platform for all authors meeting the schedule requirements below:
 - Posters will be presented in-person only. There is no option for virtual poster presentations.

- Poster sessions must be one hour each.
- Posters presented digitally. No paper posters are required or allowed.
- Authors are required to be present during scheduled poster session

CANCELLATION POLICY AND SUBSTITUTION

- All requests for refunds and/or substitutions must be submitted in writing and emailed to meetings@aaps.org.
- If you cancel your registration on/before March 21, 2023, you will be refunded your registration fee minus an administration fee of \$100 for members/non-members, or \$50 for students/postdocs members.
- No refunds will be given for "no shows" or for cancellations received on or after March 22, 2023.
- Refunds will be credited back to the original credit card used for payment.
- Substitutions from the same company may be submitted in writing at any time without penalty. If the membership status of the substitute differs from that of the original registrant, a refund or additional charge at the current rate may apply.
- Membership cancellation requests must be sent in writing by email to membership@aaps.org within 30 days of the membership start date. AAPS membership is non-transferrable and this offer is not valid if you have taken advantage of discounted member pricing during your current membership term.

ABSTRACT/POSTER WITHDRAWAL

The submitting author may withdraw their abstract or poster at any time.

To withdraw, send written notification to abstracts@aaps.org, and include:

1. Submission ID Number (Assigned Poster Number if withdrawing after Poster Schedule is issued)
2. Abstract title
3. Names of authors
4. Contact information for the submitter

AAPS will acknowledge all withdrawal notifications by email.

Withdrawal is not complete until AAPS issues notification of withdrawal to the submitting author.

POSTER REQUIREMENTS

ALL POSTERS ARE PRESENTED IN A DIGITAL FORMAT.

1

Authors must format their posters using one of the PowerPoint templates AAPS will provide. Templates include instructions and format policies that must be followed in order to have a poster accepted for presentation.

2

The poster title must match the accepted abstract word-for-word/verbatim. No edits or changes are permitted.

3

The poster must describe all the methods used and data generated by the research. Omitting data from a poster that was described in the abstract is an ethical violation that may result in the poster being removed and the author, and the organization represented by the author, being barred from future meetings.

4

Authors of accepted abstracts and posters will abide by the decisions and instructions of AAPS. In the event that authors fail to follow AAPS' policies and instructions, their posters will be removed from AAPS' online collection. Authors may also have their acceptance rescinded and, in extreme cases, may see themselves, and the organizations they represent, barred from future meetings.

5

Posters must be uploaded by the date indicated in the Important Dates section.

AAPS recommends uploading posters as soon as they are complete. All posters are reviewed prior to display by AAPS to ensure proper formatting.

FREQUENTLY ASKED QUESTIONS

Do I have to be a member of AAPS to submit an abstract?

No. Membership is not required.

Can a paper previously presented be submitted?

Encore presentations are acceptable and do not need to be referenced as an encore presentation. Previously published research is not allowed.

Who owns the copyright on the abstract and poster?

The author(s)* maintains copyright of the abstract and poster, including all proprietary rights other than copyrights, such as patent rights.

**The submitting author must ensure that all other authors know that their names will appear on the abstract.*

How will AAPS use my abstract?

If the abstract is accepted for poster presentation at the conference, the abstract will be displayed on the conference website/mobile app before, during, and after the meeting for a limited amount of time, and on the AAPS member website after the conference.

How will AAPS use my poster?

Posters, including the abstract text, data, and graphics, will be available to all conference registrants on-site throughout the meeting, and online to registrants and AAPS members for a limited time after the meeting.

Will my poster be on the app or in the Proceedings?

Your abstract and poster will appear on the conference website, available to registrants only, and will be available on the AAPS website for members-only viewing after the meeting.

POSTER ABSTRACT TRACKS/ THEMES/KEYWORDS (REVIEW GROUPS)

The 2023 AAPS National Biotechnology Conference has two tracks—each track has three themes.

SUBMITTED ABSTRACTS MUST RELATE TO A TRACK!

NOTE: On the Submission Site, the structure below—Track / Theme / Keyword(s)—is provided for you to define your Review Group. You will be prompted to select the Review Group that best fits your abstract. To do this, follow the process below.

REVIEW GROUP (Track/Theme/Keywords) SELECTION PROCESS

1 Select the TRACK that best fits your research:



ADVANCES IN THERAPEUTIC DEVELOPMENT ACROSS MODALITIES



TURBOCHARGING INNOVATION IN CMC—DRIVING BACK TO RATIONAL DRUG DESIGN

2 Select the THEME.

3 Select the KEYWORDS that best fits your research.

TRACK

THEME

KEYWORDS



TRACK 1
Advances in Therapeutic Development Across Modalities

THEME 1:

Recent Advances in Gene Therapy

- Bioanalytical Strategy
- Immunogenicity
- New Clinical Findings
- Orphan Diseases
- Pharmacodynamics
- Regulatory Guidance and Future Perspective
- Spreading, Transduction, Expression, and Duration (STED)



TRACK 1
Advances in Therapeutic Development Across Modalities





THEME 2:

The Evolution of Cellular Therapy

- Allogenic Therapies
- Autologous Therapies
- Bioanalytical Strategy
- Indications beyond Hematology
- New Technologies and Practices - Clinical Endpoints
- New Technologies and Practices - Immunophenotyping
- New Technologies and Practices - Monitoring Exposure
- Pharmacodynamics
- Regulatory Guidance and Future Perspective

continued on following page

POSTER ABSTRACT TRACKS/ THEMES/KEYWORDS (REVIEW GROUPS) CONTINUED

TRACK	THEME	KEYWORDS
 <p>TRACK 1 Advances in Therapeutic Development Across Modalities</p>	<p>THEME 3: Innovation Based on Traditional Approaches</p>	<ul style="list-style-type: none"> - Advanced Analytics - Bioanalytical Strategy - Bioengineering - Biotransformation - Immunogenicity - New Clinical Findings - Multi-specifics - New Clinical Findings - Oligonucleotides - New Clinical Findings - Vaccine-Based Therapeutics - Pharmacokinetics and Pharmacodynamics - Regulatory Guidance and Future Perspective
 <p>TRACK 2 Turbocharging Innovation in CMC—Driving Back to Rational Drug Design</p>	<p>THEME 1: Innovation Based on Non-traditional Platforms</p>	<ul style="list-style-type: none"> - Advanced Analytics - Drug Design and Analytical Tools - Emerging Opportunities and Advancements - Novel Modalities - Emerging Opportunities and Advancements - Vaccines - Regulatory Guidance and Future Perspective
 <p>TRACK 2 Turbocharging Innovation in CMC—Driving Back to Rational Drug Design</p>	<p>THEME 2: Next Generation Gene Therapies</p>	<ul style="list-style-type: none"> - Drug Design and Analytical Tools - Drug Efficacy - Critical Quality Attributes - Drug Safety - Critical Quality Attributes
 <p>TRACK 2 Turbocharging Innovation in CMC—Driving Back to Rational Drug Design</p>	<p>THEME 3: Explosion of Cell Therapy beyond CAR-T</p>	<ul style="list-style-type: none"> - Advancements and Challenges - Drug Design - Advancements and Challenges - Safety - Advancements and Challenges - Supply Chain - Allogenic Therapies - Autologous Therapies - Regulatory Guidance and Future Perspectivesw